January 17 2024
The 2023 year yielded the completion of two very important studies in the cervical cancer community. The results of these trials generated new data that will pave the way for the development of new studies for women with locally advanced cervical cancer. Furthermore, both studies had a robust representation of underrepresented minorities with NRG-GY006 having 37.5% Hispanic and Black patients, and NRG-GY017 enrolling 41% Hispanic and Black patients.
NRG-GY017 was a randomized phase I study that investigated the sequencing of immunotherapy as a primer and concurrently with chemoradiation in node positive cervical cancer. Results from the NRG-GY017 trial indicated favorable outcomes for 2-year disease-free survival and demonstrated evidence of improved immunogenicity with neoadjuvant atezolizumab in patients with locally advanced cervical cancer.
This data was presented during the plenary session at the Society of Gynecologic Oncology (SGO) 2023 Annual Meeting on Women’s Cancer and the abstract was the recipient of the SGO 2023 Presidential Award. Read the press release here.
NRG-GY006: Results from the NRG Oncology Phase III GY006 clinical study indicated that the addition of triapine to cisplatin chemoradiation did not improve overall survival outcomes for women with locally advanced cervical cancer when compared to the standard radiation therapy and cisplatin alone. NRG-GY006 demonstrated an increase in quality and technologically advanced radiation therapy with use of IMRT (74.3%) and HDR brachytherapy (98.2%).
This abstract data was presented as an oral presentation at ASCO 2023, with the abstract being published in the Journal of Clinical Oncology, available here.
More results to come in 2024!
Multiple translational studies have started, stemming from the NRG-GOG 0240 phase III clinical study of bevacizumab and chemotherapy for women with recurrent and metastatic cervical carcinoma. The results of NRG-GOG 0240 demonstrated that the incorporation of bevacizumab with chemotherapy resulted in statistically significant and clinically meaningful survival benefit for this patient population.
Patients on NRG-GOG 0240 submitted tumor samples with DNA and RNA for mutational analysis. Greater than 35,917 total mutations were identified, and >90% of mutations identified from DNA were present in RNA sequences when the expression level was sufficient. Specifically, trial results demonstrated that ARID1A and PIK3CA are potential targets and should be considered for drug development through clinical trials in the recurrent/metastatic cervical cancer space. The ongoing translational analysis from this study will enable researchers to identify potential biomarkers of response and targets for further therapeutic exploration in recurrent cervical cancer.
More information on the initial results of NRG-GOG 0240 and ongoing analysis can be found here.
Cervical Cancer Prevention Week is January 22-28, 2024
January is Cervical Cancer Prevention Month with the goal to educate about cervical cancer, its prevention, and the importance of regular screenings. Cervical cancer is a largely preventable disease, and so this serves as a reminder to prioritize cervical health and take steps to reduce the risk of this type of cancer. Learn more at https://www.cancer.gov/types/cervical